Drugs / Elsubrutinib
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04451772 | Jul 2020 → Jan 2024 | systemic lupus erythematosus | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT03978520 | Jul 2019 → Jan 2022 | systemic lupus erythematosus | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT03823378 | May 2019 → Sep 2020 | rheumatoid arthritis | AbbVie | Terminated | No outcome recorded |
| Phase 2 | NCT03682705 | Oct 2018 → Mar 2020 | rheumatoid arthritis | AbbVie | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Elsubrutinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03978520 ↗ |
| Known as | ABBV-105 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594348 ↗ |
| Action | Inhibit | “the Bruton's tyrosine kinase (BTK) inhibitor elsubrutinib” PMID 38293957 ↗ Apr 2022 |
| Modality | Small molecule | — CHEMBL4594348 ↗ |
| Route | Oral | “Elsubrutinib capsule will be administered orally.” NCT03682705 ↗ |
| Target | BTK | “the Bruton's tyrosine kinase (BTK) inhibitor elsubrutinib” PMID 38293957 ↗ Apr 2022 |